Health Medical Pharma Press Release en Mechanical engineering to aid back surgery <p>Grace O'Connell, assistant professor of mechanical engineering, heads the project to develop a systematic way to predict which patients are most vulnerable to secondary fractures or disc degeneration following spinal fusion. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Back Pain Facebook Insurance Magnetic Resonance Imaging Modeling Surgery Twitter University Berkeley Connecticut Spinal fusion medical technologies Google Bo Yang Elena Zhukova Grace O'Connell Nate Bartley surgical treatments UC Berkeley Sat, 24 Feb 2018 01:50:56 +0000 University of Berkeley 1280958 at Trustees updated on Enhancing Health theme of Penn State Strategic Plan <p>UNIVERSITY PARK, Pa. — “Enhancing Health” is one of five thematic priorities in Penn State’s Strategic Plan and calls for the University to be a leader in promoting quality of life through comprehensive approaches to enhancing personalized and population health. As part of the University’s commitment to this foundational pillar, several leaders Thursday (Feb. </p><p><a href="" target="_blank">read more</a></p> Education Health Medical Pharma Social Issues Antibiotics Cancer CEO Pennsylvania State University Public health Harrisburg Hershey, Pennsylvania Penn State Milton S. Hershey Medical Center V-12 Navy College Training Program health insurance choices mental health services tissue bank core facility PARK Penn State Health Ann Crouter Board of Trustees Cancer Institute carcinogenesis College of Agricultural Sciences and the Huck Institutes of the Life Sciences College of Health and Human Development College of Medicine Committee on Governance Craig Hillemeier Department of Health Enhancing Health Executive Committee Erin Stuart Schultz Dean Institute for Biomedical Sciences Jeffrey M. Peters National Cancer Institute opioid epidemic Penn State Cancer Institute Penn State College of Medicine Penn State Smoke Free/Tobacco Free Task Force Pennsylvania cancer sickness University Health Sciences Council Wellness Center Sat, 24 Feb 2018 00:44:50 +0000 PennState 1280947 at GOVERNMENTS OF CANADA AND MANITOBA ANNOUNCE BILATERAL AGREEMENT ON EARLY LEARNING AND CHILD CARE <p>The governments of Canada and Manitoba are investing nearly $47 million over three years to create up to 1,400 new and newly-funded early learning and child care spaces in Manitoba, Families Minister Scott Fielding announced today.  Fielding was joined at the announcement by Dan Vandal, member of Parliament for St. Boniface–St. Vital, on behalf of Families, Children and Social Development Minister Jean-Yves Duclos, at Morrow Avenue Child Care Programs for Families – Rene Deleurme Centre in St. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Social Issues Child care Education Family Movies Manitoba Canadian Child Care Federation Child and family services Early childhood education Euthenics National Childcare Accreditation Council child care services child-care services co-ordinating services supportive family services workforce and improving child-care services the manitoba Bonnie Ash Dan Vandal Federal Government Government of Canada Jean-Yves Duclos northern Manitoba Parliament for St. Boniface–St Rene Deleurme Centre Scott Fielding Fri, 23 Feb 2018 19:55:31 +0000 MFCB 1280798 at Cancer Agency Awards More Than $3 Million to University of Texas at Austin Scientists <p>AUSTIN, Texas – Three awards totaling $3.19 million from the Cancer Prevention and Research Institute of Texas (CPRIT) will support cancer research in The University of Texas at Austin’s Departments of Molecular Biosciences and Chemistry. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Human Interest Cancer Cancer research Ovarian cancer Prostate cancer Surgery University of Texas at Austin Austin cancer prevention Molecular Biosciences acute lymphoblastic leukemia Cancer Prevention and Research Institute of Texas diseases Everett Stone glioblastoma inborn errors of metabolism Lauren Ehrlich Livia Schiavinato Eberlin tumors Fri, 23 Feb 2018 18:49:28 +0000 University of Texas 1280742 at U.S. hospitals testing experimental therapies to prevent two common bacterial infections <p>NIH-funded sites join large, international clinical trials. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Antibiotics AstraZeneca Bacteria Cancer Disease Ebola Medicine Microbiology US Federal Agency World Health Organization Brussels North Carolina Paris Rockville Antibiotic-resistant bacteria Bacteremia Bacterial diseases Gram-positive bacteria Healthcare-associated infections National Institute of Allergy and Infectious Diseases Pathogenic bacteria Pseudomonas aeruginosa Staphylococcus aureus healthcare settings healthcare-associated infections search identifiers weakened immune systems GAITHERSBURG Antibacterial Resistance Leadership Group innovative medicines initiative MedImmune NIAID Anthony S. Fauci Antibiotic therapy antibodies aureus-related disease aureus-related pneumonia bacteremia bloodstream infections bone infections both common and rare diseases Bruno Francis catheters Centers for Disease Control and Prevention Centre Hospitalier Universaitaire de Limoges diseases Duke University, Durham healthcare-associated infections incident pneumonia infections infectious and immune-mediated diseases Jean Chastre mechanical ventilation methicillin-resistant S. aureus National Institute of Health P. aeruginosa infections pneumonia Pseudomonas S. aureus serious infections severe, hard-to-treat bacterial infections Thomas Holland U.S. Department of Health and Human Services Fri, 23 Feb 2018 18:22:26 +0000 NIH 1280813 at United States Files False Claims Act Complaint Against Compounding Pharmacy, Private Equity Firm, and Two Pharmacy Executives Alleging Payment of Kickbacks <p>The United States has filed a complaint in intervention against Diabetic Care Rx LLC d/b/a Patient Care America (PCA), a compounding pharmacy located in Pompano Beach, Florida, alleging that the pharmacy paid illegal kickbacks to induce prescriptions for compounded drugs reimbursed by TRICARE, the Department of Justice announced today.  The government has also brought claims against Patrick Smith and Matthew Smith, two pharmacy executives, and Riordan, Lewis &amp; Haden Inc. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Law Law Medical prescription Pain Pharmacy Pharmacy Special agent United States Department of Defense US Federal Agency Los Angeles POMPANO BEACH Washington DC Defense Criminal Investigative Service Qui tam TRICARE medical care and services Diabetic Care Rx LLC Patient Care America Riordan, Lewis & Haden Inc. TRICARE Ada Lopez Branch Chad A. Readler Criminal Investigative Service Department of Defense Department of Justice John F. Khin Justice Department’s Civil Division Marisela Medrano Matthew Smith Patrick Smith Randy Hummel scar Southeast Field Office telemedicine U.S. Army Criminal Investigation Command’s Major Procurement Fraud Unit U.S. Attorney’s office for the Southern District of Florida U.S. District Court for the Southern District of Florida U.S. Food and Drug Administration’s office of Criminal Investigations United States Attorney’s office for the Southern District of Florida Fri, 23 Feb 2018 18:20:56 +0000 DOJ 1280764 at Pfizer Announces Update on European Marketing Authorization Application for SUTENT (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma NEW YORK--( )--Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended against expanding use of SUTENT&reg; (sunitinib) to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma (RCC) following nephrectomy (surgical removal of the cancerous kidney). The CHMP&rsquo;s recommendation is not binding but will now be taken into consideration by the European Commission (EC). There is currently no approved adjuvant treatment option available for patients with non-metastatic RCC at high risk for recurrence in the European Union (EU). <p><a href="" target="_blank">read more</a></p> Health Medical Pharma Back Pain Cancer Cancer treatments Diabetes Disease European Union Facebook Healthcare Immunotherapy Linkedin Medicine NASDAQ Oncology Pain Pharmaceuticals Surgery U.S. Securities and Exchange Commission Youtube New York City France Clinical medicine Indoles Kidney cancer Pfizer Placebo Pyrroles Renal cell carcinoma Sunitinib biopharmaceutical consumer health care products health care products Lyon FMS New England Journal pfizer global Pfizer Inc. world cancer research fund international abdominal pain advanced pNET advanced renal cell carcinoma arthralgia bradycardia congestive heart failure constipation contraception cortical blindness cough diarrhea dysgeusia dyspnea epistaxis erythema multiforme European Commission European Medicines Agency fasciitis fatal liver failure fatigue feared diseases fever gastrointestinal stromal tumor hand-foot syndrome headache hematologic cancers hemolytic uremic syndrome high tumor hyperglycemia hyperkalemia hypertension hyperthyroidism hypoglycemia Hypothyroidism immunotherapies International Agency for Research kidney cancer leukopenia liver failure loss of consciousness lymphopenia Mace Rothenberg male and female infertility metastatic disease mucositis/stomatitis myocardial infarction myocardial ischemia nausea Necrotizing fasciitis nephrotic syndrome neutropenia normal and cardiac failure osteonecrosis pancreatitis pNET progressive, well-differentiated pancreatic neuroendocrine tumors Proteinuria pulmonary hemorrhage pulmonary tumors Rash recurrent renal cell carcinoma relevant pre-existing cardiac disease renal cell carcinoma renal failure Reversible posterior leukoencephalopathy syndrome seizures severe and life-threatening hemoptysis severe hypertension solid tumors Stevens-Johnson syndrome stomatitis SUTENT® (sunitinib) symptomatic hypoglycemia thrombocytopenia thrombotic thrombocytopenic purpura Thyroid dysfunction thyroiditis Torsades de Pointes toughest cancers toxic epidermal necrolysis tumor Tumor Lysis Syndrome U.S. Food and Drug Administration vomiting Fri, 23 Feb 2018 17:49:41 +0000 Pfizer 1280696 at Albert Bourla Elected to Pfizers Board of Directors <p>NEW YORK--( )--Pfizer Inc. today announced the election of Albert Bourla, DVM, Ph.D. to its Board of Directors, effective immediately. </p><p><a href="" target="_blank">read more</a></p> Business Finance Health Medical Pharma Biotechnology Biotechnology Consumer Customer Economy of New York City Healthcare Linkedin NASDAQ Oncology Pharmaceutical industry Pharmaceuticals Vaccines Youtube Europe New York City Africa Middle East President Pfizer biopharmaceutical business groups consumer health care products health care products Inflammation and Immunology Internal Medicine Pfizer Inc. Albert Bourla Biotechnology Innovation Organization Executive Committee feared diseases Veterinary School Fri, 23 Feb 2018 17:40:35 +0000 Pfizer 1280698 at International Development Minister praises Birmingham research supporting UK aid during University visit <p>UK aid is driving huge breakthroughs in medicine, nutrition and agriculture to help the world’s poorest people, International Development Minister Alistair Burt said in a speech to academics and students on his visit to the University of Birmingham. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma AIDS Antibiotics Christmas Disease Global health Infection Public health Sanitation University Vaccination Vaccine World Health Organization Birmingham UK Bangladesh Department for International Development Euthenics Extreme poverty University of Birmingham Wellcome Trust Alistair Burt bacterial infections Department of Health diphtheria diseases epidemics gastrointestinal surgery Global Challenges Research Fund middle income countries fight deadly diseases miscarriage polio Tim Softley UK Medical Research Council University of Birmingham World Health Organisation years malaria Fri, 23 Feb 2018 17:06:13 +0000 University of Birmingham 1280757 at Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG and BOSULIF NEW YORK--( )--Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union (EU). MYLOTARG&trade; (gemtuzumab ozogamicin) in combination with daunorubicin and cytarabine has been granted a positive opinion for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia (AML), except acute promyelocytic leukemia (APL). BOSULIF&reg; (bosutinib) has been granted a positive opinion for the treatment of adults with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). <p><a href="" target="_blank">read more</a></p> Health Medical Pharma Cancer Cancer treatments Chemotherapy Disease European Union Facebook Healthcare Infection Leukemia Linkedin Manufacturing Medicine NASDAQ Oncology Pain Pharmaceuticals Rare diseases U.S. Securities and Exchange Commission Youtube Europe New York City Philadelphia Japan RTT Acute myeloid leukemia Antineoplastic drugs CD33 Clinical medicine Gemtuzumab ozogamicin Piperazines biopharmaceutical consumer health care products health care products leukemia treatment medicinal products Online Analysis/Prediction Celltech Leukemia &amp; Lymphoma Society MAB Pfizer Inc. SFJ Pharmaceuticals Group UCB abdominal pain ABOUT ACUTE MYELOID LEUKEMIA acute leukemia acute myeloid leukemia acute promyelocytic leukemia ADC American Cancer Society anaphylactic shock anaphylaxis anemia bone marrow cancer BOSULIF bronchospasm CD33 CD33-positive acute myeloid leukemia chills chromosome-positive chronic myelogenous leukemia chronic myelogenous leukemia Chronic myeloid leukemia chronic phase Ph+ CML chronic phase Philadelphia clinically significant hypotension combination chemotherapy constipation contraception cough diarrhea Drug-induced liver injury dyspnea European Commission European Medicines Agency fatal hepatic veno-occlusive disease fatigue feared diseases fever headache hematologic cancers hypersensitivity hypotension immunotherapies increased ALT Leukemia & Lymphoma Society Mace Rothenberg mucositis MYLOTARG nausea neutropenia newly-diagnosed chronic phase Philadelphia pericardial effusion persistent thrombocytopenia using dose delay pleural effusion prolonged thrombocytopenia pulmonary edema rare blood cancer Rash renal dysfunction Respiratory Failure single-agent cancer sinusoidal obstruction syndrome solid tumors tachycardia thrombocytopenia toughest cancers U.S. Food and Drug Administration veno-occlusive liver disease vomiting Fri, 23 Feb 2018 17:04:05 +0000 Pfizer 1280705 at Penn State Childrens Hospital expansion project advanced by board committee <p>UNIVERSITY PARK, Pa. — Final plans to add three floors to the Penn State Children’s Hospital building on the campus of Penn State Health Milton S. Hershey Medical Center were recommended Thursday (Feb. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Health University Boston Pennsylvania Bergan Mercy Medical Center Intensive care medicine Intensive care unit University of Missouri Women's and Children's Hospital inpatient services PARK ANTE C-Section Payette Associates Children’s Hospital Neonatal Intensive Care Unit Pediatric Acute Care Unit Pediatric Intermediate Care Unit Penn State Children’s Hospital Penn State Health Milton S. Hershey Medical Center Post-Partum Unit Trustees Committee on Finance Fri, 23 Feb 2018 15:38:01 +0000 PennState 1280657 at Health Officials Confirm Second Pediatric Flu Death of 2017-2018 Season <p>This page has been automatically translated from English. MSDH has not reviewed this translation and is not responsible for any inaccuracies. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Flu Infection Influenza Influenza vaccine Medicine Jackson 2017–18 United States flu season Clinical medicine Flu pandemic Flu pandemic in the United States by state Flu season Influenza A virus subtype H1N1 Influenza-like illness Swine influenza healthcare providers MSDH Public Health Laboratory agency monitors flu Centers for Disease Control and Prevention central Mississippi cough extremely active flu fatigue fever flu virus H3N2 flu headache illness individual flu Influenza-Like Illness Mississippi State Department muscle aches only pediatric flu pediatric flu pediatric influenza primarily causing illness seasonal flu sore throat Fri, 23 Feb 2018 15:04:51 +0000 MSDH 1280640 at NIH launches international study of AMD progression <p>Natural history investigation will deploy latest advances to identify biomarkers, targets for early therapy. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Diabetes Disease Medicine US Federal Agency Vision Rockville Germany UK Italy Australia President Adaptation Drusen Eye Fundus photography Macula of retina Macular degeneration National Eye Institute Ophthalmology Retina AMD blindness both common and rare diseases complex, multifactorial disease Doheny Eye Institute early age-related macular degeneration early stage disease Emily Y. Chew eye diseases Federal Government late disease late-stage disease National Eye Institute National Institute of Health NEI Division of Epidemiology and Clinical Applications retinal disease Stephen J. Ryan tomography U.S. Department of Health and Human Services Fri, 23 Feb 2018 13:46:24 +0000 NIH 1280652 at Lynparza receives positive EU CHMP opinion in platinum-sensitive relapsed ovarian cancer <p>AstraZeneca and Merck &amp; Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorisation of Lynparza (olaparib) tablets (300mg twice daily) for use as a maintenance therapy for patients with platinum-sensitive relapsed high grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete response or partial response to platinum-based chemotherapy. Lynparza is recommended for treatment in this setting regardless of patients’ BRCA mutation status. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma AstraZeneca Cancer Chemotherapy Disease European Union Infection Medicine NASDAQ Neuroscience Neuroscience Oncology Ovarian cancer Pharmaceuticals London United States Canada RTT Clinical medicine Lactams Olaparib PARP inhibitors Piperazines Treatment of cancer broader cancer treatment science-led biopharmaceutical Acerta Pharma European Network for Gynaecological Oncological Trial Groups Groupe d’Investigateurs National Merck & Co. Inc. MSD Research Laboratories 300mg Lynparza breast and blood cancers cancers Committee for Medicinal Products for Human Use common cancer diseases dizziness dysgeusia European Medicines Agency fatigue FDA headache long-term disease Lynparza Lynparza (olaparib) tablets metabolic diseases metastatic breast cancer nausea platinum-sensitive relapsed ovarian cancer primary peritoneal cancer relapsed ovarian cancer relapsed, high-grade serous ovarian cancer Roy Baynes Sean Bohen tumour tumour types vomiting Fri, 23 Feb 2018 11:35:17 +0000 AstraZeneca 1280613 at Physical exercise reduces risk of developing diabetes - study <p>Higher levels of walking, jogging or running are linked to a lower risk of diabetes in high-risk individuals. </p><p><a href="" target="_blank">read more</a></p> Health Medical Pharma Diabetes Diabetes mellitus Diabetes mellitus type 1 Endocrine system Insulin University Birmingham Taipei China American Diabetes Association Endocrinology Epidemiology of diabetes mellitus IFG Impaired fasting glucose Prediabetes diabetes prevention academia sinica American Diabetes Association China’s growing obesity epidemic China’s ongoing obesity epidemic Chinese University of Hong Kong MJ Health Research Foundation Neil Thomas observed diabetes Sports Medicine Tony Moran University of Birmingham University of Birmingham’s Institute of Applied Health Research vascular and chronic kidney disease World Health Organisation Fri, 23 Feb 2018 11:07:42 +0000 University of Birmingham 1280582 at